FDA approves first CGRP antagonist nasal spray for acute migraine

Zavegepant (Zavzpret), a nasally administered small molecule calcitonin gene-related peptide (CGRP) receptor antagonist, is indicated for the treatment of acute migraine with or without aura in adults. It's not indicated for migraine prevention. The most common adverse events in clinical trials were dysgeusia, nasal discomfort, nausea, and vomiting.